Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Loading...
Loading...
Repligen Corporation
RGEN
announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc.
PFE
to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).
Market News and Data brought to you by Benzinga APIs
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...